UCB

Patient centricity

UCB focuses directly on the needs of patients, by including them in our work.

Some development projects already have patient advisory councils and we have patient group alliances in the development and marketing functions of the company. This enables us to understand their needs, through regular and open dialogue. Questions that are directly relevant to patients are increasingly being included into trial documentation.

Some of our colleagues are themselves patients, and this provides valuable insights. We encourage physicians on our research teams to remain close to clinical practice, and encourage all of our staff to meet and learn from patients. Through regular contact with patients we can understand the significant physical and social consequences of living with severe diseases.

 

UK Patient Organisations

UCB works with a number of patient organisations in the UK. In order that these activities are transparent, clause 27.7 of the UK ABPI Code of Practice 2015 edition requires that each company must make publicly available, at a national or European level, a list of patient organisations to which it provides financial support and/or significant indirect/non-financial support, which must include short descriptions of the nature of the support that is sufficiently complete to enable the average reader to form an understanding of the significance of the support.

For further information, click here.

 

Contracted Services –
UK Patient Organisations 2014

Clause 27.8 of the 2015 ABPI Code requires Pharmaceutical companies to make publicly available, at a national or European level, a list of patient organisations that it has engaged to provide significant contracted services.

For further information, click here.

 

 

UK Partnerships

Establishing successful partnerships is fundamental to the success of UCB as the complexities of severe diseases are beyond the expertise and resource of a single organisation. Through partnerships, UCB can optimise its product pipeline in its core therapeutic areas.

The Centre for Collaborative Research (CfCR) is based in Slough, and supports collaboration with academics and biotech companies to investigate new targets for possible development.
The CfCR aims to develop new collaborative projects with academic and biotechnology partners by providing access to UCB’s world-class antibody generation and engineering capabilities. The CfCR is currently seeking project proposals in the area of immunology. Key areas of interest include, but are not limited to:

  • rheumatology, for example rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)
  • severe asthma and chronic obstructive pulmonary disease (COPD)
  • osteoarthritis and osteoporosis
  • fibrotic disease and scleroderma
  • immune tolerance.

Collaboration

Collaborations have been established with scores of academic institutions and leading drug discovery organisations in the UK to improve discovery, research and early clinical stage development. UCB also supports research conducted by other UK organisations.

UCB purchasing

Global Purchasing supports UCB’s overall supply requirements through strategic sourcing, integrated business processes and data management.

UCB Pharma

The UK premises of UCB are located in Slough, Berkshire. The site at Slough houses the immunology research hub and the head office for the British and Irish Isles (BII) commercial organisation.

 

Antibody research and early antibody development functions are also located in Slough alongside some manufacturing and corporate functions.

 

208 Bath Road
Slough SL1 3WE
Telephone: 01753 534 655

 

www.ucbpharma.co.uk

  • North America Analysis
  • Cranfield University - Woman as Leaders Programme